Oxytetracycline


Concise Prescribing Info
Indications/Uses
Listed in Dosage.
Dosage/Direction for Use
Adult: PO Susceptible infections 250-500 mg 4 times/day. Max: 4 g/day. Acne 250-500 mg twice daily. Uncomplicated gonorrhoea Initial: 1.5 g, then 0.5 g 4 times/day, up to a total of 9 g/treatment course. IM Susceptible infections 250 mg once daily. Ophth Superficial ophth infections W/ other agents: As oint: Apply 2-4 times/day. As susp: Instill 1-2 drops 3 times/day. Topical Infected dermatitis W/ topical steroid: Apply up to 4 times/day.
Administration
Should be taken on an empty stomach. Take on an empty stomach 1 hr before or 2 hr after meals.
Contraindications
Hypersensitivity to tetracyclines, children <8 yr, renal damage. Pregnancy, lactation.
Special Precautions
Elderly, renal or hepatic impairment; myasthenia gravis; lupus erythematosus, children <12 yr.
Adverse Reactions
Anorexia, nausea, vomiting,diarrhoea, glossitis, dysphagia, photosensitivity, oesphageal irritation and ulceration, nephrotoxicity, enterocolitis, rash (rare), blood dyscrasias. Headache, visual disturbances; intracranial hypertension; bulging fontanelles (infants).
Potentially Fatal: Rare. Fulminant diarrhoea in post operative patients.
Drug Interactions
Antacids, iron, aluminum, calcium, magnesium, zinc salts reduce absorption. Concurrent use may cause increased levels of lithium, digoxin, halofantrine and theophylline; decreased concentrations of atovaquone. Increased risk of ergotism with ergot alkaloids. May cause failure of oral contraception.
ATC Classification
J01AA06 - oxytetracycline ; Belongs to the class of tetracyclines. Used in the systemic treatment of infections.
G01AA07 - oxytetracycline ; Belongs to the class of antibiotics. Used in the treatment of gynecological infections.
D06AA03 - oxytetracycline ; Belongs to the class of topical tetracycline and derivatives agents used in the treatment of dermatological diseases.
S01AA04 - oxytetracycline ; Belongs to the class of antibiotics. Used in the treatment of eye infections.
Disclaimer: This information is independently developed by CIMS based on oxytetracycline from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in